Cutaneous Adverse Events of Targeted Therapies for Hematolymphoid Malignancies

Publication date: Available online 14 July 2017 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Julia D. Ransohoff, Bernice Y. Kwong The identification of oncogenic drivers of liquid tumors has led to the rapid development of targeted agents with distinct cutaneous adverse event (AE) profiles. The diagnosis and management of these skin toxicities has motivated a novel partnership between dermatologists and oncologists in developing supportive oncodermatology clinics. Here we review the current state of knowledge of clinical presentation, mechanisms, and management of the most common and significant cutaneous AEs observed during treatment with targeted therapies for hematologic and lymphoid malignancies. We systematically review by drug-targeting pathway the cutaneous AE profiles of these drugs, and offer insight when possible into whether pharmacologic target versus immunologic modulation primarily underlie presentation. We include discussion of tyrosine kinase inhibitors (Imatinib, Dasatinib, Nilotinib, Bosutinib, Ponatinib), Blinatumomab, Ibrutinib, Idelalisib, anti-B cell antibodies (Rituximab, Ibritumomab, Obinutuzumab, Ofatumumab, Tositumomab), immune checkpoint inhibitors (Nivolumab, Pembrolizumab), Alemtuzumab, Brentuximab, and proteasome inhibitors (Bortezomb, Carfilzomib, Ixazomib). We highlight skin reactions seen with anti-liquid but not solid tumor agents, draw attention to serious cutaneous AEs that may require therapy modification or cessation, and ...

Source: Clinical Lymphoma Myeloma and Leukemia - July 14, 2017 Category: Cancer & Oncology Source Type: research